ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results: A Look into the Company's Strong Performance and Future Growth Potential

ChromaDex Corp. (NASDAQ:CDXC), a leader in nicotinamide adenine dinucleotide (NAD+) research focusing on healthy aging, has scheduled its Fourth Quarter and Fiscal Year 2024 financial results conference call for March 4, 2025, at 4:30 p.m. ET. The financial results will be released after market close on the same day. The company will host an investor conference call to discuss Q4 and FY2024 results, providing a general business update. Participants are advised to join 10 minutes before the call using the toll-free number 888.596.4144 with Conference ID 8584242. A webcast replay will be available until March 11, 2025.

ChromaDex's strong financial performance in the third quarter of 2024 highlights the company's growth potential. The company reported total net sales of $25.6 million, marking a 31% increase year-over-year. This growth was driven by a 368% increase in Niagen ingredient sales, which rose to $6.7 million, and a 4% increase in Tru Niagen sales. The company also achieved a gross margin of 63.5% and recorded net income of $1.9 million, or $0.02 per share, surpassing analyst estimates of $0.00 earnings per share and $23.64 million in revenue.



ChromaDex's strategic focus on expanding its Niagen+ product line has contributed to its robust financial performance. The expansion into wellness clinics and the introduction of pharmaceutical-grade Niagen products have opened new revenue streams. However, the company faces challenges such as increased operating expenses, which rose by 12% to $14.6 million, primarily due to higher sales and marketing expenses and legal costs associated with the Niagen+ launch. To manage these costs effectively, ChromaDex is focusing on careful cost management as it scales its operations.

Looking ahead to the fourth quarter and fiscal year 2024 financial results, investors can expect to see continued growth in Niagen ingredient sales and Tru Niagen sales. The company's ability to innovate and expand its product offerings will be critical in maintaining its competitive edge and driving future growth. ChromaDex's performance in Q3 2024 underscores its growing financial strength and positions the company for continued success in the bioscience sector.



In conclusion, ChromaDex's strong financial performance in the third quarter of 2024, driven by its strategic focus on expanding its Niagen+ product line, positions the company for continued growth and success in the bioscience sector. Investors can expect to see continued trends in Niagen ingredient sales and Tru Niagen sales in the fourth quarter and fiscal year 2024 financial results. However, investors should also be aware of the increase in operating expenses and the need for careful cost management as the company scales its operations. As ChromaDex continues to innovate and expand its product offerings, it is well-positioned to maintain its competitive edge and drive future growth in the bioscience sector.